Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carfilzomib with Hyper-CVAD in Newly Diagnosed ALL/Lymphoma
NCT02293109Phase 1Completed
- Start
- Dec 2015
- Primary completion
- Dec 2017
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of carfilzomib in acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LL). Primary endpoint: Maximum Tolerated Dose up to 56 days. Started Dec 2015; status: completed.
02
Drugs
carfilzomib
03
Conditions
acute lymphoblastic leukemia (ALL)lymphoblastic lymphoma (LL)
Beyond the preview
Go deeper on NCT02293109.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02293109.